Customize your JAMA Network experience by selecting one or more topics from the list below.
Ku JH, Winthrop KL, Varley CD, et al. Implications for Biologic Therapy: Staphylococcus aureus Decolonization of Individuals With a History of Recurrent Skin and Soft-Tissue Infections. JAMA Dermatol. 2013;149(8):986–989. doi:10.1001/jamadermatol.2013.4405
Patients with immune-mediated inflammatory diseases (IMIDs) are at an increased risk for skin and soft-tissue infections (SSTIs),1 presumably owing to colonizing organisms like Staphylococcus aureus.1 Although few organism-level data are available by which to judge whether these agents increase the risk of S aureus infection specifically, biologic therapies widely used to treat IMIDs have been shown to increase the risk of SSTIs and other serious infections, complicating therapeutic management of IMIDs.2,3 Although staphylococcal decolonization therapy has been used in various health care settings, no description of such therapy exists for patients with IMIDs with recurrent SSTIs on biologic therapies. For those patients with recurrent infections thought to be due to S aureus, decolonization could theoretically provide protection against subsequent infection.
Create a personal account or sign in to: